Article

HLA-G engineering reprograms CAR-T cells with an immune privilege

2026-05-13

Abstract excerpt

Personalized T cell therapy empowered by chimeric antigen receptor (CAR) that recognizes specific tumor antigen has cured numerous blood cancer patients since its initial approval in 2017. However, its access to a broader population has been limited by the unavailability of an off-the-shelf product derived from an allogeneic donor that can evade immune rejection, which is mediated by polymorphic class I and class...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: acd1ee2d-6b76-50b3-b50c-1953e20b64d7
DOI: 10.64898/2026.05.10.723228

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HLA-G engineering reprograms CAR-T cells with an immune privilegeDOI 10.64898/2026.05.10.723228Read

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.Semantic proximity Read

HLA ‐G 2012 conference: the 15‐year milestone updateSemantic proximity Read

Allogeneic CAR-T Cells: Engineering Around Host ImmunitySemantic proximity Read

The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune CellsSemantic proximity Read

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read

HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune DiseaseSemantic proximity Read

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?Semantic proximity Read

Matching or genetic engineering of HLA Class I and II facilitates successful allogeneic ‘off-the-shelf’ regulatory T cell therapySemantic proximity Read

Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonismSemantic proximity Read

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?Semantic proximity Read

Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapySemantic proximity Read

Current status and perspective of CAR-T and CAR-NK cell therapy trials in GermanySemantic proximity Read